Pharmaceutical companies navigate a new peptide policy
The policy change put verified manufacturing, purity, testing, and patient safety at the center of supplier review.
In October 2026, the Department of Health and Human Services introduced a conditional compounding policy covering six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. This is not FDA approval. It is a limited enforcement-discretion policy for qualifying pharmacies and physicians.
- Customer: **Six Peptides
- Solution: In October 2026, the Department of Health and Human Services introduced a conditional compounding policy covering six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax
A conditional policy puts six peptides under tighter scrutiny
In October 2026, the Department of Health and Human Services introduced a conditional compounding policy covering six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax.
Verified manufacturers become the focus of supply decisions
It's about scientific evidence, traceability, and regulatory accountability.
Traceability and accountability define the new peptide opportunity
For pharmaceutical companies, the new opportunity is defined by traceability and accountability.
The US peptide industry is entering a new chapter.
In practice, that means supply decisions now turn on what can be verified, what can be tested, and what can be defended. Companies reviewing options can start with the Peptides Products page to assess fit against those needs.
If you need a compliant peptide supply partner, explore Niner Pharma’s Peptides Products.
